Diabetes drugs and stroke risk: Intensive versus conventional glucose‐lowering strategies, and implications of recent cardiovascular outcome trials

People with diabetes mellitus are at higher risk of ischaemic stroke and worse outcomes thereafter. However, whether it is better to prescribe intensive glucose‐lowering treatment compared with conventional treatment in people with diabetes to prevent recurrent stroke is debated. It is also crucial...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism Vol. 22; no. 1; pp. 6 - 15
Main Authors: Lim, Soo, Oh, Tae Jung, Dawson, Jesse, Sattar, Naveed
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01-01-2020
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:People with diabetes mellitus are at higher risk of ischaemic stroke and worse outcomes thereafter. However, whether it is better to prescribe intensive glucose‐lowering treatment compared with conventional treatment in people with diabetes to prevent recurrent stroke is debated. It is also crucial to consider whether specific antidiabetic agents are more efficacious and safer than others for prevention of stroke. In this review, we provide an overview of the efficacy of intensive and conventional glucose‐lowering treatment in post‐stroke management. Our conclusion is that the overall evidence for a beneficial effect of intensive glycaemic control on risk of stroke is limited. We also discuss evidence from recent large clinical trials of thiazolidinediones and new antidiabetic medications, including dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), and sodium‐glucose co‐transporter‐2 inhibitors. On the basis of the findings of these trials, our conclusion is that pioglitazone and the GLP‐1RA class (other than short‐acting lixisenatide) are likely to lessen the occurrence of cerebrovascular disease (by mechanisms not dependent on glucose‐lowering per se), whereas there is no consistent evidence for other drug classes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.13850